'New Technologies to Capture Over 10% of the Antibody Therapeutics Market by 2023' Shows Visiongain Report

LONDON, February 7, 2013 /PRNewswire/ --

A new report by Visiongain shows that next-generation technologies will become a major driver for the antibody therapeutics market. Worth just under $170m in 2012, the new wave of products will represent over 10% of all antibody therapeutics revenues by the end of 2023. Antibody-drug conjugates (ADCs) are leading the way, but Fc-engineered, bispecific, and biosimilar antibodies, as well as next-generation fragments and antibody-like proteins will also show high revenue growth to 2023, the study predicts. That revenue forecast and others appear in Next-Generation Antibody Therapeutics Market 2013-2023, published in February 2013.

Signs that next-generation antibody development is coming to fruition include the 2011 FDA approval of Seattle Genetics' Adcetris (brentuximab vedotin) and the 2012 approval in Japan of Kyowa Hakko Kirin's Poteligeo (mogamulizumab). Poteligeo is the first approved mAb with glycosylation patterns engineered for improved efficacy. Biosimilar antibodies came a step closer in 2012 too, with the South Korean approval of CellTrion's Remsima. The potential of next-generation technologies was underlined when Amgen acquired Micromet and its bispecific T-cell engager (BiTE) platform, also in 2012.

James Evans, a pharmaceutical industry analyst in visiongain, said: "Antibody therapeutics will be the first, second and third-highest selling pharma products in 2013. But the massive achievements of the antibodies sector need to be renewed by next-generation products. We're approaching a situation where every druggable target has been tried, the market is getting saturated, the low-hanging fruit has gone. The market needs new kinds of products to keep it moving.

"With the EMA guidance in place, biosimilar antibodies will soon light a fire under the sector, increasing competition and forcing innovator companies to start differentiating their antibody products. The next-generation platforms offer a kind of toolkit for doing differentiation and lifecycle management. You can see Roche getting in on the ground floor there with what they're doing with obinituzumab and T-DM1, using engineering and ADC technologies to extend their rituximab and trastuzumab franchises. T-DM1 is potentially a major watershed for the next-generation field, because it's the first ADC against a solid tumour target. Adcetris has had a pretty ordinary start in commercial terms, but in any case it's a lymphoma treatment. The real question is whether ADC approaches can give mAbs the potency to start hitting solid tumours.

"Bispecifics aren't as far along as ADCs or glycoengineered mAbs yet, but blinatumomab is looking good, and Amgen clearly thinks so too. Also at the heavily re-engineered end of the technology spectrum, a few of the small proteins, both Ig-based and alternative scaffolds, have got into phase 2 testing. The Allergan DARPin has got people's attention in the AMD field, for example. None of those platforms have made it all the way yet, but the R&D is continuing, and big pharma is watching closely there too."

Visiongain forecasts a CAGR of over 50% for the next-generation market through 2023, as the novel technologies advance across a broad front and new antibody modalities gain validation and acceptance by the industry.

The analyses include revenue forecasts to 2023 for two overall world markets:

• Therapeutic antibodies (overall sales)

• Next-generation therapeutic antibodies.

They also include submarket forecasts to 2023 for five next-generation technologies:

• Engineered antibodies

• Antibody-drug conjugates (ADCs)

• Bispecific antibodies (bisAbs)

• Antibody fragments and antibody-like proteins

• Biosimilar antibody products.

Visiongain's study discusses R&D and commercial prospects. It shows research interviews too. Next-Generation Antibody Therapeutics Market 2013-2023 adds to the company's range of analytical reports on emerging industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Next-Generation Antibody Therapeutics Market 2013-2023 please visit: http://www.visiongain.com/Report/978/Next-Generation-Antibody-Therapeutics-Market-2013-2023

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44-(0)20-7336-6100

Notes for Editors

Companies Listed

Abbott Laboratories
Ablynx
Adnexus
Affibody
Affimed Therapeutics
Agensys
Alcon
Alexion Pharmaceuticals
Alexis Biotech
Algeta
Allergan
Allozyme
Ambrx
American Society of Clinical Oncology
Amgen
Amylin
Applied Molecular Evolution
Aprogen
Arana Therapeutics
Astellas Pharma
AstraZeneca
Avesthagen
Baxter
Bayer Healthcare
Bayer Schering
BayTech Venture Capital
Biocon
Biogen Idec
Biolex Therapeutics
BioTech Pharma
Biotecnol
Biotest Pharmaceuticals
Biovitrum AB
BioWa
Boehringer Ingelheim
Borean Pharma
Bradmer Pharmaceuticals
Bristol-Myers Squibb
Cancer Research Technology
Cancer Research UK
Cell Therapeutics
Celldex Therapeutics
Celltech
Celltrion
Cephalon
Cevec Pharmaceuticals
Chengdu Hoist Biotech
CIMYM Biosciences
Corixa Corporation
Covagen
Crucell
CytomX Therapeutics
Daiichi Sankyo
Delenex Therapeutics
Dendreon
Diversys
Domantis
Dr. Reddy's Laboratories
Dresden University of Technology
Elan Pharmaceuticals
Eli Lilly
Emergent BioSolutions
Epigen Biotech
ESBATech
EuroFarma
European Medicines Agency (EMEA/EMA)
Fabrus
Food and Drug Administration (US FDA)
Forbion Capital
Fresenius
Gedeon Richter
Genentech
Genmab
Gilde Healthcare Partners
GlaxoSmithKline (GSK)
Global Life Science Ventures
GlycArt
Glycotope
GTV Biotherapeutics
Hanwha Chemical
Haptogen
Heidelberg Pharma
Human Genome Sciences
IBC Pharmaceuticals
Igenica
Immunocore
ImmunoGen
Immunomedics
Isu Abxis
Janssen Biotech (formerly Centocor Ortho Biotech)
Johnson & Johnson
Karolinska Institute
Krankenhaus Nordwest (Frankfurt am Main)
Kyowa Hakko Kirin
Laboratoires Français de Fractionnement et des Biotechnologies (LFB)
LG Life Sciences
Life Science Pharmaceuticals
Lonza
Ludwig Institute for Cancer Research
Mabgene
MacroGenics
Medarex
MedImmune
Meiji Seika Pharma
Memorial Sloan-Kettering Cancer Center
Mentrik Biotech
Merck & Co.
Merck KGaA
Merck Serono
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus Biopharmaceuticals
Micromet
Millennium Pharmaceuticals
Ministry of Health, Labour and Welfare (MHLW, Japan)
Molecular Partners
MorphoSys
National Institute for Health and Clinical Excellence (NICE, UK)
Nerviano Medical Sciences
Novartis
Nuclisome
Oncoscience
OrbiMed Advisors
Oslo University Hospital
Oxford BioMedica
Peptech Corporation
Percivia
Pfizer
Pharming Healthcare
Pieris
Probiomed
Progenics Pharmaceuticals
RBC Capital Markets
ReceptorLogic
Redwood Bioscience
Regeneron Pharmaceuticals
Roche
Roslin Institute
Samsung
Sandoz
Sanofi
Scil Proteins
SeaGen Secure
Seattle Genetics
Shanghai CP Guojian
Soroka University Medical Centre
Spectrum Pharmaceuticals
Spirogen
Stada
Sutro Biopharma
Swedish Orphan Biovitrum
Swiss Federal Institute of Technology
Symphogen
Syntarga
Takeda Pharmaceutical Company
Technische Universität München
Teva Pharmaceutical Industries
TG Therapeutics
Tufts Centre for Drug Discovery
UCB
University of Aberdeen
University of Oxford
Viragen
Viropharma
Wacker Biosolutions
Wyeth (now part of Pfizer)
Xencor
Zenotech 

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)207-336 6100